IP Library › Granted Patent US 12,673,981
Granted Patent B2
US 12,673,981 · App. 18/310,141 · Granted Jul 7, 2026

T cell receptors recognizing HLA-CW8 restricted mutated KRAS

Inventors: Eric Tran (Portland, OR); Yong-Chen Lu (Little Rock, AR); Steven A. Rosenberg (Potomac, MD)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
C07K14/7051C07K14/82G01N33/57575A61K38/00G01N2333/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,673,981
App. No.
18/310,141
Filed
May 1, 2023
Granted
Jul 7, 2026
Kind
B2
Art Unit
1644
USPC
514/19.3
Abstract

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

Claims (139)

1 . A method of producing an engineered population of human cells, the method comprising:

introducing a recombinant expression vector to an isolated population of human cells, wherein the recombinant expression vector comprises a nucleotide sequence encoding a T cell receptor (TCR), wherein the TCR comprises:

(a) an α chain complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 3, an α chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and an α chain CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and

(b) a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8.

2 . The method of claim 1 , wherein the TCR has antigenic specificity for KRAS G12D.

3 . The method of claim 2 , wherein the KRAS G12D is presented by a human leukocyte antigen (HLA)-Cw8 molecule.

4 . The method of claim 1 , wherein the TCR comprises:

(a) an α chain variable region comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 9;

(b) a β chain variable region comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 10;

(c) an α chain variable region comprising an amino acid sequence at least 99% identical to amino acids 20-129 of SEQ ID NO: 9;

(d) a β chain variable region comprising an amino acid sequence at least 99% identical to amino acids 22-132 of SEQ ID NO: 10; or

(e) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d).

5 . The method of claim 1 , wherein the TCR comprises:

(a) an α chain variable region comprising the amino acid sequence of SEQ ID NO: 9;

(b) a β chain variable region comprising the amino acid sequence of SEQ ID NO: 10;

(c) an α chain variable region comprising amino acids 20-129 of SEQ ID NO: 9;

(d) a β chain variable region comprising amino acids 22-132 of SEQ ID NO: 10; or

(e) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d).

6 . The method of claim 1 , wherein the TCR further comprises:

(a) an α chain constant region comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 11, wherein:

(i) X at position 48 of SEQ ID NO: 11 is Thr or Cys;

(ii) X at position 112 of SEQ ID NO: 11 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 of SEQ ID NO: 11 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 115 of SEQ ID NO: 11 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain constant region comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 12, wherein X at position 57 of SEQ ID NO: 12 is Ser or Cys; or

(c) both (a) and (b).

7 . The method of claim 1 , wherein the TCR further comprises:

(a) an α chain constant region comprising the amino acid sequence of SEQ ID NO: 11, wherein:

(i) X at position 48 of SEQ ID NO: 11 is Thr or Cys;

(ii) X at position 112 of SEQ ID NO: 11 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 of SEQ ID NO: 11 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 115 of SEQ ID NO: 11 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain constant region comprising the amino acid sequence of SEQ ID NO: 12, wherein X at position 57 of SEQ ID NO: 12 is Ser or Cys; or

(c) both (a) and (b).

8 . The method of claim 1 , wherein the TCR comprises:

(a) an α chain comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 13, wherein:

(i) X at position 177 of SEQ ID NO: 13 is Thr or Cys;

(ii) X at position 241 of SEQ ID NO: 13 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 243 of SEQ ID NO: 13 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 244 of SEQ ID NO: 13 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 14, wherein X at position 189 of SEQ ID NO: 14 is Ser or Cys;

(c) an α chain comprising an amino acid sequence at least 99% identical to amino acids 20-266 of SEQ ID NO: 13, wherein:

(i) X at position 177 of SEQ ID NO: 13 is Thr or Cys;

(ii) X at position 241 of SEQ ID NO: 13 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 243 of SEQ ID NO: 13 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 244 of SEQ ID NO: 13 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(d) a β chain comprising an amino acid sequence at least 99% identical to amino acids 22-305 of SEQ ID NO: 14, wherein X at position 189 of SEQ ID NO: 14 is Ser or Cys; or

(e) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d).

9 . The method of claim 1 , wherein the TCR comprises:

(a) an α chain comprising the amino acid sequence of SEQ ID NO: 13, wherein:

(i) X at position 177 of SEQ ID NO: 13 is Thr or Cys;

(ii) X at position 241 of SEQ ID NO: 13 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 243 of SEQ ID NO: 13 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 244 of SEQ ID NO: 13 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain comprising the amino acid sequence of SEQ ID NO: 14, wherein X at position 189 of SEQ ID NO: 14 is Ser or Cys;

(c) an α chain comprising amino acids 20-266 of SEQ ID NO: 13, wherein:

(i) X at position 177 of SEQ ID NO: 13 is Thr or Cys;

(ii) X at position 241 of SEQ ID NO: 13 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 243 of SEQ ID NO: 13 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 244 of SEQ ID NO: 13 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(d) a β chain comprising amino acids 22-305 of SEQ ID NO: 14, wherein X at position 189 of SEQ ID NO: 14 is Ser or Cys; or

(e) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d).

10 . A method for inducing an immune response against a cancer in a mammal, the method comprising administering to the mammal a population of host cells in an amount effective to induce an immune response against the cancer in the mammal, wherein the cancer expresses human leukocyte antigen (HLA)-Cw8 and Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D and wherein the host cells of the population comprise a recombinant expression vector comprising a nucleic acid comprising a nucleotide sequence encoding a T-cell receptor (TCR) having antigenic specificity for KRAS G12D presented by an HLA-Cw8 molecule, and wherein the TCR comprises:

(I) an α chain complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 3, an α chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and an α chain CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and

(II) a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 6, a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8.

11 . The method of claim 10 , wherein the TCR comprises:

(a) an α chain variable region comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 9;

(b) a β chain variable region comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 10;

(c) an α chain variable region comprising an amino acid sequence at least 99% identical to amino acids 20-129 of SEQ ID NO: 9;

(d) a β chain variable region comprising an amino acid sequence at least 99% identical to amino acids 22-132 of SEQ ID NO: 10; or

(e) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d).

12 . The method of claim 10 , wherein the TCR comprises:

(a) an α chain variable region comprising the amino acid sequence of SEQ ID NO: 9;

(b) a β chain variable region comprising the amino acid sequence of SEQ ID NO: 10;

(c) an α chain variable region comprising amino acids 20-129 of SEQ ID NO: 9;

(d) a β chain variable region comprising amino acids 22-132 of SEQ ID NO: 10; or

(e) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d).

13 . The method of claim 10 , wherein the TCR further comprises:

(a) an α chain constant region comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 11, wherein:

(i) X at position 48 of SEQ ID NO: 11 is Thr or Cys;

(ii) X at position 112 of SEQ ID NO: 11 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 of SEQ ID NO: 11 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 115 of SEQ ID NO: 11 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain constant region comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 12, wherein X at position 57 of SEQ ID NO: 12 is Ser or Cys; or

(c) both (a) and (b).

14 . The method of claim 10 , wherein the TCR further comprises:

(a) an α chain constant region comprising the amino acid sequence of SEQ ID NO: 11, wherein:

(i) X at position 48 of SEQ ID NO: 11 is Thr or Cys;

(ii) X at position 112 of SEQ ID NO: 11 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 of SEQ ID NO: 11 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 115 of SEQ ID NO: 11 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain constant region comprising the amino acid sequence of SEQ ID NO: 12, wherein X at position 57 of SEQ ID NO: 12 is Ser or Cys; or

(c) both (a) and (b).

15 . The method of claim 10 , wherein the TCR comprises:

(a) an α chain comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 13, wherein:

(i) X at position 177 of SEQ ID NO: 13 is Thr or Cys;

(ii) X at position 241 of SEQ ID NO: 13 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 243 of SEQ ID NO: 13 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 244 of SEQ ID NO: 13 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain comprising an amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO: 14, wherein X at position 189 of SEQ ID NO: 14 is Ser or Cys;

(c) an α chain comprising an amino acid sequence at least 99% identical to amino acids 20-266 of SEQ ID NO: 13, wherein:

(i) X at position 177 of SEQ ID NO: 13 is Thr or Cys;

(ii) X at position 241 of SEQ ID NO: 13 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 243 of SEQ ID NO: 13 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 244 of SEQ ID NO: 13 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(d) a β chain comprising an amino acid sequence at least 99% identical to amino acids 22-305 of SEQ ID NO: 14, wherein X at position 189 of SEQ ID NO: 14 is Ser or Cys; or

(e) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d).

16 . The method of claim 10 , wherein the TCR comprises:

(a) an α chain comprising the amino acid sequence of SEQ ID NO: 13, wherein:

(i) X at position 177 of SEQ ID NO: 13 is Thr or Cys;

(ii) X at position 241 of SEQ ID NO: 13 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 243 of SEQ ID NO: 13 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 244 of SEQ ID NO: 13 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain comprising the amino acid sequence of SEQ ID NO: 14, wherein X at position 189 of SEQ ID NO: 14 is Ser or Cys;

(c) an α chain comprising amino acids 20-266 of SEQ ID NO: 13, wherein:

(i) X at position 177 of SEQ ID NO: 13 is Thr or Cys;

(ii) X at position 241 of SEQ ID NO: 13 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 243 of SEQ ID NO: 13 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 244 of SEQ ID NO: 13 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(d) a β chain comprising amino acids 22-305 of SEQ ID NO: 14, wherein X at position 189 of SEQ ID NO: 14 is Ser or Cys; or

(e) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d).

17 . An isolated or purified nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising a functional portion of a T-cell receptor (TCR) having antigenic specificity for KRAS G12D presented by an HLA-Cw8 molecule, wherein the functional portion comprises the amino acid sequences of SEQ ID NOs: 3-8.

18 . The nucleic acid of claim 17 , wherein the functional portion comprises the amino acid sequences of (I) SEQ ID NO: 9; (II) SEQ ID NO: 10; or (III) SEQ ID NOs: 9-10.

19 . The nucleic acid of claim 17 , further comprising:

(a) the amino acid sequence of SEQ ID NO: 11, wherein:

(i) X at position 48 of SEQ ID NO: 11 is Thr or Cys;

(ii) X at position 112 of SEQ ID NO: 11 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 of SEQ ID NO: 11 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 115 of SEQ ID NO: 11 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) the amino acid sequence of SEQ ID NO: 12, wherein X at position 57 of SEQ ID NO: 12 is Ser or Cys; or

(c) both (a) and (b).

20 . The nucleic acid of claim 17 , comprising:

(a) the amino acid sequence of SEQ ID NO: 13, wherein:

(i) X at position 177 of SEQ ID NO: 13 is Thr or Cys;

(ii) X at position 241 of SEQ ID NO: 13 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 243 of SEQ ID NO: 13 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 244 of SEQ ID NO: 13 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) the amino acid sequence of SEQ ID NO: 14, wherein X at position 189 of SEQ ID NO: 14 is Ser or Cys; or

(c) both (a) and (b).

Continuity (4)
Continuation 16739310 · Jan 10, 2020
Continuation 15758954 · Sep 9, 2016
Provisional Application 62218688 · Sep 15, 2015
Related Publication 20230406904A1 · Dec 21, 2023
References Cited (50)
US 8034334B2 · Dudley et al. · 2011 [cited by applicant]
US 8383099B2 · Dudley et al. · 2013 [cited by applicant]
US 10117918B2 · Sabin et al. · 2018 [cited by applicant]
US 20050037455A1 · Kolesnick et al. · 2005 [cited by applicant]
US 20120244133A1 · Rosenberg et al. · 2012 [cited by applicant]
US 20140378389A1 · Robbins et al. · 2014 [cited by applicant]
US 20170304421A1 · Wang et al. · 2017 [cited by applicant]
JP 2013541332A · 2013 [cited by applicant]
JP 2014528714A · 2014 [cited by applicant]
JP 2017536825A · 2017 [cited by applicant]
WO WO2007017201A1 · 2007 [cited by applicant]
WO WO2015022520A1 · 2015 [cited by applicant]
WO WO2016085904A1 · 2016 [cited by applicant]
Bonehill et al., “Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules,” [cited by applicant]
Bristol et al., “Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization,” [cited by applicant]
Cohen et al., “Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond,” [cited by applicant]
Dudley et al., “Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients,” [cited by applicant]
Garcia et al., “How the T Cell Receptor Sees Antigen—A Structural View”, [cited by applicant]
Gjertsen et al., “HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes,” [cited by applicant]
Gros et al., “PD-1 identifies the patient-specific CD8 [cited by applicant]
Haga-Friedman et al., “Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity,” [cited by applicant]
Imamura et al., “Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers”, [cited by applicant]
International Bureau, International Search Report and Written Opinion in International Application No. PCT/US2016/050875, mailed Nov. 11, 2016. [cited by applicant]
Janeway et al., Immunobiology, 5 [cited by applicant]
Japanese Patent Office, Official Action in counterpart Japanese Patent Application No. 513423/2018, mailed Sep. 8, 2020. [cited by applicant]
Jin et al., “Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to Nos. needed for patient treatment,” [cited by applicant]
Jones et al., “Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma,” [cited by applicant]
Kloosterboer et al., “Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-… [cited by applicant]
Kubuschok et al., “Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer,” [cited by applicant]
Lu et al., “Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions,” [cited by applicant]
Manning et al., “Alanine Scanning Mutagenesis of an αβ T cell receptor: mapping the energy of antigen recognition”, [cited by applicant]
Portolano et al., “Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain ‘Roulette’”, [cited by applicant]
Qin et al., “CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients,” [cited by applicant]
Riddell et al., “The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells,” [cited by applicant]
Robins et al., “Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells”, [cited by applicant]
Rosenberg et al., “Adoptive cell transfer as personalized immunotherapy for human cancer,” [cited by applicant]
Rosenberg, “T cells as a Drug for the Personalized Immunotherapy of Cancer,” [cited by applicant]
Shono et al., “Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers,” [cited by applicant]
Tran et al., “Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer,” [cited by applicant]
Tran et al., “Immunogenicity of somatic mutations in human gastrointestinal cancers” and Supplementary Materials, [cited by applicant]
Tran, “Cell transfer therapy against somatic mutations in human gastrointestinal cancers,” presentation given at 8 [cited by applicant]
Tran, “Immunogenicity and immunotherapeutic targeting of somatic mutations inhuman gastrointestinal cancers,” presentation given at 15 [cited by applicant]
Tran, “Immunogenicity and immunotherapeutic targeting of somatic mutations in human gastrointestinal cancers,” presentation given during a visit to Ottawa Hospital Research Institute, Ottawa, ON, on Jul. 10, 2015. [cited by applicant]
Tsai et al., “K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif,” [cited by applicant]
Wang et al., “Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors,” [cited by applicant]
Catalogue of Somatic Mutations in Cancer (COSMIC), entry for GRCh38, //cancer.sanger.ac.uk/cosmic/mutation/overview?id=107970345, printed Dec. 1, 2025. [cited by applicant]
Kompier et al., “FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy”, PLoS One, 5(11): e13821, pp. 1-13 (2010). [cited by applicant]
Mirkovic et al., “Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract”, Modern Pathology, 28: 1504-1514 (2015). [cited by applicant]
Stephen et al., “Dragging Ras Back in the Ring”, Cancer Cell, 25: 272-281 (2014). [cited by applicant]
Murphy et al., eds., [cited by applicant]